NFκB and Cyclic AMP Response Element Sites Mediate the Valproic Acid and UL138 Responsiveness of the Human Cytomegalovirus Major Immediate Early Enhancer and Promoter

• Published in: Journal of virology 2023-03, Vol.97 (3), p.e0002923-e0002923
• Main Authors: Albright, Emily R, Walter, Ryan M, Saffert, Ryan T, Kalejta, Robert F
• Format: Article
• Language: English
• Subjects: Cyclic AMP - metabolism; Cytomegalovirus - physiology; Gene Expression Regulation, Viral; Genome and Regulation of Viral Gene Expression; Genome Replication and Regulation of Viral Gene Expression; Humans; NF-kappa B - genetics; NF-kappa B - metabolism; Response Elements; Valproic Acid - metabolism; Valproic Acid - pharmacology; Viral Proteins - genetics; Viral Proteins - metabolism; Virology
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/jvi.00029-23

The major immediate early enhancer and promoter (MIEP) of human cytomegalovirus (HCMV) drives the transcription of the immediate early one (IE1) and IE2 genes, whose encoded proteins stimulate productive, lytic replication. The MIEP is activated by the virally encoded and tegument-delivered pp71 protein at the start of lytic infections of fully differentiated cells. Conversely, the MIEP is silenced at the start of latent infections within incompletely differentiated myeloid cells in part because tegument-delivered pp71 is sequestered in the cytoplasm in these cells, but also by viral factors that repress transcription from this locus, including the UL138 protein. During both modes of infection, MIEP activity can be increased by the histone deacetylase inhibitor valproic acid (VPA); however, UL138 inhibits the VPA-responsiveness of the MIEP. Here, we show that two families of cellular transcription factors, NF-κB and cAMP response element-binding protein (CREB), together control the VPA-mediated activation and UL138-mediated repression of the HCMV MIEP. Artificial regulation of the HCMV MIEP, either activation or repression, is an attractive potential means to target the latent reservoirs of virus for which there is currently no available intervention. The MIEP could be repressed to prevent latency reactivation or induced to drive the virus into the lytic stage that is visible to the immune system and inhibited by multiple small-molecule antiviral drugs. Understanding how the MIEP is regulated is a critical part of designing and implementing either strategy. Our revelation here that NF-κB and CREB control the responsiveness of the MIEP to the viral UL138 protein and the FDA-approved drug VPA could help in the formulation and execution of promoter regulatory strategies against latent HCMV.